The roles of HIV-1 proteins and antiretroviral drug therapy in HIV-1-associated endothelial dysfunction

Journal of Investigative Medicine

Volumn 56, Issue 5, 2008, Pages 752-769

  Kline, Erik R ^a   Sutliff, Roy L ^a,b  

^a EMORY UNIVERSITY   (United States)

^b Mailstop 151 P ^*  (United States)

Author keywords

AZT; Cardiovascular disease; Endothelium; Gp120; HIV; Nef; NNRTI; NRTI; PI; Tat

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIOXIDANT; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EMTRICITABINE; ENFUVIRTIDE; GLYCOPROTEIN GP 120; INDINAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; MARAVIROC; NEF PROTEIN; NELFINAVIR; NITRIC OXIDE SYNTHASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TRANSACTIVATOR PROTEIN; UNINDEXED DRUG; VIRUS PROTEIN; VPR PROTEIN; VPU PROTEIN; ZALCITABINE; ZIDOVUDINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ATHEROSCLEROSIS; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL STRESS; DIABETES MELLITUS; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERLACTATEMIA; HYPERLIPIDEMIA; HYPERSENSITIVITY REACTION; IN VITRO STUDY; IN VIVO STUDY; LACTIC ACIDOSIS; LIFE EXPECTANCY; LIPODYSTROPHY; LOW DRUG DOSE; METABOLIC DISORDER; MOLECULAR MECHANICS; MYOPATHY; NONHUMAN; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PANCREATITIS; PERIPHERAL NEUROPATHY; QUALITY OF LIFE; REVIEW; VASCULAR ENDOTHELIUM; VIRUS GENE; VIRUS INFECTIVITY; VIRUS LOAD; VIRUS REPLICATION; CARDIOVASCULAR SYSTEM; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATHOGENICITY; PATHOPHYSIOLOGY; PHYSIOLOGY; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; ENDOTHELIUM, VASCULAR; HIV INFECTIONS; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; OXIDATIVE STRESS;

EID: 49149083348     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.1097/jim.0b013e3181788d15     Document Type: Review

References (214)

1. Reisler RB, Han C, Burman WJ, et al. Grade 4 events are as important as AIDS events in the era of HAART. J Acquir Immune Defic Syndr. 2003;34(4):379-386.
2. Joshi VV, Pawel B, Connor E, et al. Arteriopathy in children with acquired immune deficiency syndrome. Pediatr Pathol. 1987;7(3):261-275.
3. Paton P, Tabib A, Loire R, et al. Coronary artery lesions and human immunodeficiency virus infection. Res Virol. 1993;144(3):225-231.
4. Mandell BF, Calabrese LH. Infections and systemic vasculitis. Curr Opin Rheumatol. 1998;10(1):51-57.
5. Cebrian M, Miro O, Font C, et al. HIV-related vasculitis. AIDS Patient Care STDS. 1997;11(4):245-258.
6. Maniker AH, Hunt CD. Cerebral aneurysm in the HIV patient: a report of six cases. Surg Neurol. 1996;46(1):49-54.
7. Grunfeld C, Pang M, Doerrler W, et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74(5):1045-1052.
8. Schved JF, Gris JC, Arnaud A, et al. von Willebrand factor antigen, tissue-type plasminogen activator antigen, and risk of death in human immunodeficiency virus 1-related clinical disease: independent prognostic relevance of tissue-type plasminogen activator. J Lab Clin Med. 1992;120(3):411-419.
9. Lafeuillade A, Alessi MC, Poizot-Martin I, et al. Endothelial cell dysfunction in HIV infection. J Acquir Immune Defic Syndr. 1992;5(2):127-131.
10. Wolf K, Tsakiris DA, Weber R, et al. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis. 2002;185(4):456-462.
11. Greenwood AJ, Hughes J, Wallace G, et al. Soluble intercellular adhesion molecule-1 (sICAM-1) and vascular cell adhesion molecule-1 (sVCAM-1) in patients with HIV/AIDS does not appear to correlate with cytomega-lovirus retinitis. Int J STD AIDS. 1998;9(11):713-714.
12. Seigneur M, Constans J, Blann A, et al. Soluble adhesion molecules and endothelial cell damage in HIV infected patients. Thromb Haemost. 1997;77(4):646-649.
13. Klein D, Hurley LB, Quesenberry CP Jr, et al. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr. 2002;30(5):471-477.
14. Triant VA, Lee H, Hadigan C, et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92(7):2506-2512.
15. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283-2296.
16. Blum A, Hadas V, Burke M, et al. Viral load of the human immunodeficiency virus could be an independent risk factor for endothelial dysfunction. Clin Cardiol. 2005;28(3):149-153.
17. Solages A, Vita JA, Thornton DJ, et al. Endothelial function in HIV-infected persons. Clin Infect Dis. 2006; 42(9):1325-1332.
18. Bonnet D, Aggoun Y, Szezepanski I, et al. Arterial stiffness and endothelial dysfunction in HIV-infected children. AIDS. 2004;18(7):1037-1041.
19. Lorenz MW, Stephan C, Harmjanz A, et al. Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis. Jan 31 2007.
20. Turner BG, Summers MF. Structural biology of HIV. J Mol Biol. 1999;285(1):1-32.
21. Krogstad P. Molecular biology of the human immunodeficiency virus: current and future targets for intervention. Semin Pediatr Infect Dis. 2003;14(4):258-268.
22. Corbeil J, Evans LA, McQueen PW, et al. Productive in vitro infection of human umbilical vein endothelial cells and three colon carcinoma cell lines with HIV-1. Immunol Cell Biol. 1995;73(2):140-145.
23. Fan ST, Hsia K, Edgington TS. Upregulation of human immunodeficiency virus-1 in chronically infected mono-cytic cell line by both contact with endothelial cells and cytokines. Blood. 1994;84(5):1567-1572.
24. Conaldi PG, Serra C, Dolei A, et al. Productive HIV-1 infection of human vascular endothelial cells requires cell proliferation and is stimulated by combined treatment with interleukin-1 beta plus tumor necrosis factor-alpha. J Med Virol. 1995;47(4):355-363.
25. Moses AV, Bloom FE, Pauza CD, et al. Human immunodeficiency virus infection of human brain capillary endothelial cells occurs via a CD4/galactosylceramide-independent mechanism. Proc Natl Acad Sci U S A. 1993;90(22):10474-10478.
26. Poland SD, Rice GP, Dekaban GA. HIV-1 infection of human brain-derived microvascular endothelial cells in vitro. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8(5):437-445.
27. Ades EW, Comans TW, Nicholson JK, et al. Lack of evidence that human immunodeficiency virus can infect human endothelial cells in vitro. J Acquir Immune Defic Syndr. 1993;6(1):104.
28. Ades EW, Nicholson JK, Browning SW, et al. Inability of human immunodeficiency virus to infect human microvascular endothelial cells. Pathobiology. 1992;60(6):330-331.
29. Liu NQ, Lossinsky AS, Popik W, et al. Human immunodeficiency virus type 1 enters brain microvascular endothelia by macropinocytosis dependent on lipid rafts and the mitogen-activated protein kinase signaling pathway. J Virol. 2002;76(13):6689-6700.
30. Gujuluva C, Burns AR, Pushkarsky T, et al. HIV-1 penetrates coronary artery endothelial cells by transcy-tosis. Mol Med. 2001;7(3):169-176.
31. An SF, Groves M, Giometto B, et al. Detection and localisation of HIV-1 DNA and RNA in fixed adult AIDS brain by polymerase chain reaction/in situ hybridisation technique. Acta Neuropathol (Berl). 1999;98(5):481-487.
32. An SF, Groves M, Gray F, et al. Early entry and widespread cellular involvement of HIV-1 DNA in brains of HIV-1 positive asymptomatic individuals. J Neuropathol Exp Neurol. 1999;58(11):1156-1162.
33. Bagasra O, Lavi E, Bobroski L, et al. Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: identification by the combination of in situ polymerase chain reaction and immunohistochemistry. AIDS. 1996;10(6):573-585.
34. Fiala M, Looney DJ, Stins M, et al. TNF-alpha opens a paracellular route for HIV-1 invasion across the blood-brain barrier. Mol Med. 1997;3(8):553-564.
35. Shiu C, Barbier E, Di Cello F, et al. HIV-1 gp120 as well as alcohol affect blood-brain barrier permeability and stress fiber formation: involvement of reactive oxygen species. Alcohol Clin Exp Res. 2007;31(1):130-137.
36. Fiala M, Eshleman AJ, Cashman J, et al. Cocaine increases human immunodeficiency virus type 1 neuroin-vasion through remodeling brain microvascular endothelial cells. J Neurovirol. 2005;11(3):281-291.
37. Chi D, Henry J, Kelley J, et al. The effects of HIV infection on endothelial function. Endothelium. 2000; 7(4):223-242.
38. Maslin CL, Kedzierska K, Webster NL, et al. Transen-dothelial migration of monocytes: the underlying molecular mechanisms and consequences of HIV-1 infection. Curr HIV Res. 2005;3(4):303-317.
39. Kofler S, Nickel T, Weis M. Role of cytokines in cardiovascular diseases: a focus on endothelial responses to inflammation. Clin Sci (Lond). 2005;108(3):205-213.
40. Sudano I, Spieker LE, Noll G, et al. Cardiovascular disease in HIV infection. Am Heart J. 2006;151(6):1147-1155.
41. Copeland KF. Modulation of HIV-1 transcription by cytokines and chemokines. Mini Rev Med Chem. 2005; 5(12):1093-1101.
42. Mu H, Chai H, Lin PH, et al. Current Update on HIV-associated Vascular Disease and Endothelial Dysfunction. World J Surg. 2007;31(4):632-643.
43. Clark S, Duggan J, Chakraborty J. Tsl and LP-BM5: a comparison of two murine retrovirus models for HIV. Viral Immunol. 2001;14(2):95-109.
44. Baliga RS, Chaves AA, Jing L, et al. AIDS-related vasculopathy: evidence for oxidative and inflammatory pathways in murine and human AIDS. Am J Physiol Heart Circ Physiol. 2005;289(4):H1373-H1380.
45. Gillespie MN, Hartsfield CL, O'Connor WN, et al. Pulmonary hypertension in a murine model of the acquired immunodeficiency syndrome. Am J Respir Crit Care Med. 1994;150(1):194-199.
46. Naeije R, Rondelet B. Pathobiology of pulmonary arterial hypertension. Bull Mem Acad R Med Belg. 2004; 159(Pt 2):219-226.
47. Seoane L, Shellito J, Welsh D, et al. Pulmonary hypertension associated with HIV infection. South Med J. 2001;94(6):635-639.
48. Speich R, Jenni R, Opravil M, et al. Primary pulmonary hypertension in HIV infection. Chest. 1991;100(5): 1268-1271.
49. Pugliese A, Isnardi D, Saini A, et al. Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement. J Infect. 2000;40(3):282-284.
50. Zuber JP, Calmy A, Evison JM, et al. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis. 2004;38(8):1178-1185.
51. Sitbon O, Lascoux-Combe C, Delfraissy JF, et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med. 2008;177(1):108-113.
52. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340(2):115-126.
53. Jones DP. Redefining oxidative stress. Antioxid Redox Signal. 2006;8(9-10):1865-1879.
54. Castro L, Rodriguez M, Radi R. Aconitase is readily inactivated by peroxynitrite, but not by its precursor, nitric oxide. J Biol Chem. 1994;269(47):29409-29415.
55. Hausladen A, Fridovich I. Superoxide and peroxynitrite inactivate aconitases, but nitric oxide does not. J Biol Chem. 1994;269(47):29405- 29408.
56. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol. Nov 1996;271(5 Pt 1):C1424-C1437.
57. Wink DA, Mitchell JB. Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radic Biol Med. 1998; 25(4-5):434-456.
58. Gewaltig MT, Kojda G. Vasoprotection by nitric oxide: mechanisms and therapeutic potential. Cardiovasc Res. 2002;55(2):250-260.
59. Fenster BE, Tsao PS, Rockson SG. Endothelial dysfunction: clinical strategies for treating oxidant stress. Am Heart J. 2003;146(2):218-226.
60. Zafari AM, Ushio-Fukai M, Akers M, et al. Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy. Hypertension. 1998;32(3): 488-495.
61. Shankar SS, Dube MP. Clinical aspects of endothelial dysfunction associated with human immunodeficiency virus infection and antiretroviral agents. Cardiovasc Toxicol. 2004;4(3):261-269.
62. Pace GW, Leaf CD. The role of oxidative stress in HIV disease. Free Radic Biol Med. 1995;19(4):523-528.
63. Baruchel S, Wainberg MA. The role of oxidative stress in disease progression in individuals infected by the human immunodeficiency virus. J Leukoc Biol. 1992;52(1): 111-114.
64. Favier A, Sappey C, Leclerc P, et al. Antioxidant status and lipid peroxidation in patients infected with HIV. Chem Biol Interact. 1994;91(2-3):165-180.
65. Elbim C, Pillet S, Prevost MH, et al. Redox and activation status of monocytes from human immunodeficiency virus-infected patients: relationship with viral load. J Virol. 1999;73(6):4561-4566.
66. Peterhans E. Reactive oxygen species and nitric oxide in viral diseases. Biol Trace Elem Res. 1997;56(1):107-116.
67. Buhl R, Jaffe HA, Holroyd KJ, et al. Systemic glutathione deficiency in symptom-free HIV-seropositive individuals. Lancet. 1989;2(8675):1294- 1298.
68. Dröge W, Eck HP, Mihm S. Oxidant-antioxidant status in human immunodeficiency virus infection. In: Packer L, ed. Oxygen Radicals in Biological Systems. San Diego, CA: Academic Press; 1994:594-601.
69. Droge W, Eck HP, Mihm S. HIV-induced cysteine deficiency and T-cell dysfunction-a rationale for treatment with N-acetylcysteine. Immunol Today. 1992;13(6):211-214.
70. Stephensen CB, Marquis GS, Jacob RA, et al. Vitamins C and E in adolescents and young adults with HIV infection. Am J Clin Nutr. 2006;83(4):870-879.
71. Delmas-Beauvieux MC, Peuchant E, Couchouron A, et al. The enzymatic antioxidant system in blood and glutathione status in human immunodeficiency virus (HIV)-infected patients: effects of supplementation with selenium or beta-carotene. Am J Clin Nutr. 1996;64(1): 101-107.
72. Barditch-Crovo P, Noe D, Skowron G, et al. A phase I/II evaluation of oral L-2-oxothiazolidine-4-carboxylic acid in asymptomatic patients infected with human immunodeficiency virus. J Clin Pharmacol. 1998;38(4):357-363.
73. Akerlund B, Jarstrand C, Lindeke B, et al. Effect of N- acetylcysteine(NAC) treatment on HIV-1 infection: a double-blind placebo-controlled trial. Eur J Clin Pharmacol. 1996;50(6):457-461.
74. Allard JP, Aghdassi E, Chau J, et al. Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV-infected subjects. Aids. 1998;12(13): 1653-1659.
75. Merchant AT, Msamanga G, Villamor E, et al. Multi-vitamin supplementation of HIV-positive women during pregnancy reduces hypertension. J Nutr. 2005;135(7): 1776-1781.
76. Constans J, Seigneur M, Blann AD, et al. Effect of the antioxidants selenium and beta-carotene on HIV-related endothelium dysfunction. Thromb Haemost. 1998;80(6): 1015-1017.
77. de Souza Junior O, Treitinger A, Baggio GL, et al. alpha-Tocopherol as an antiretroviral therapy supplement for HIV-1-infected patients for increased lymphocyte viability. Clin Chem Lab Med. 2005;43(4):376-382.
78. Hurwitz BE, Klaus JR, Llabre MM, et al. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. Arch Intern Med. 2007;167(2):148-154.
79. Palmieri C, Trimboli F, Puca A, et al. Inhibition of HIV-1 replication in primary human monocytes by the IkappaB-alphaS32/36A repressor of NF-kappaB. Retrovirology. 2004;1:45.
80. Victoriano AF, Asamitsu K, Hibi Y, et al. Inhibition of human immunodeficiency virus type 1 replication in latently infected cells by a novel IkappaB kinase inhibitor. Antimicrob Agents Chemother. 2006;50(2):547-555.
81. Williams SA, Kwon H, Chen LF, et al. Sustained induction of NF-kappa B is required for efficient expression of latent human immunodeficiency virus type 1. J Virol. 2007;81(11):6043-6056.
82. Alcami J, Lain de Lera T, Folgueira L, et al. Absolute dependence on kappa B responsive elements for initiation and Tat-mediated amplification of HIV transcription in bloodCD4Tlymphocytes. Embo J. 1995;14(7):1552-1560.
83. Beauparlant P, Kwon H, Clarke M, et al. Transdominant mutants of I kappa B alpha block Tat-tumor necrosis factor synergistic activation of human immunodeficiency virus type 1 gene expression and virus multiplication. J Virol. 1996;70(9):5777-5785.
84. Harhaj E, Blaney J, Millhouse S, et al. Differential effects of I kappa B molecules on Tat-mediated transactivation of HIV-1 LTR. Virology. 1996;216(1):284-287.
85. Ho WZ, Starr SE, Sison A, et al. L-2-oxothiazolidine-4-carboxylic acid inhibits human immunodeficiency virus type 1 replication in mononuclear phagocytes and lymphocytes. Clin Diagn Lab Immunol. 1997;4(3):352-357.
86. Oiry J, Puy JY, Mialocq P, et al. Synthesis and in vitro anti-HIV activity in human monocyte-derived macro-phages of 2-oxothiazolidine-4(R)- carboxylic acid derivatives. J Med Chem. 1999;42(23):4733-4740.
87. Lederman MM, Georges D, Dando S, et al. L-2-oxothiazolidine-4-carboxylic acid (procysteine) inhibits expression of the human immunodeficiency virus and expression of the interleukin-2 receptor alpha chain. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8(2):107-115.
88. Raju PA, Herzenberg LA, Herzenberg LA, et al. Glutathione precursor and antioxidant activities of N-acetylcysteine and oxothiazolidine carboxylate compared in in vitro studies of HIV replication. AIDS Res Hum Retroviruses. 1994;10(8):961-967.
89. Jacob BA, Porter KM, Elms SC, et al. HIV-1-induced pulmonary oxidative and nitrosative stress: exacerbated response to endotoxin administration in HIV-1 transgenic mouse model. Am J Physiol Lung Cell Mol Physiol. 2006;291(4):L811-L819.
90. Goldstein G. HIV-1 Tat protein as a potential AIDS vaccine. Nat Med. 1996;2(9):960-964.
91. Chang HC, Samaniego F, Nair BC, et al. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. Aids. 1997;11(12):1421-1431.
92. Poggi A, Carosio R, Fenoglio D, et al. Migration of V delta 1 and V delta 2 T cells in response to CXCR3 and CXCR4 ligands in healthy donors and HIV-1-infected patients: competition by HIV-1 Tat. Blood. 2004;103(6): 2205-2213.
93. Paladugu R, Fu W, Conklin BS, et al. Hiv Tat protein causes endothelial dysfunction in porcine coronary arteries. J Vasc Surg. 2003;38(3):549-555; discussion 555-546.
94. Chen F, Lu Y, Castranova V, et al. Nitric oxide inhibits HIV tat-induced NF-kappaB activation. Am J Pathol. 1999;155(1):275-284.
95. Liu X, Jana M, Dasgupta S, et al. Human immunodeficiency virus type 1 (HIV-1) tat induces nitric-oxide synthase in human astroglia. J Biol Chem. 2002;277(42): 39312-39319.
96. Park IW, Wang JF, Groopman JE. HIV-1 Tat promotes monocyte chemoattractant protein-1 secretion followed by transmigration of monocytes. Blood. 2001;97(2): 352-358.
97. Pu H, Tian J, Flora G, et al. HIV-1 Tat protein upregulates inflammatory mediators and induces monocyte invasion into the brain. Mol Cell Neurosci. 2003;24(1):224-237.
98. Dhawan S, Puri RK, Kumar A, et al. Human immunodeficiency virus-1-tat protein induces the cell surface expression of endothelial leukocyte adhesion molecule-1, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in human endothelial cells. Blood. 1997;90(4):1535-1544.
99. Liu K, Chi DS, Li C, et al. HIV-1 Tat protein-induced VCAM-1 expression in human pulmonary artery en-dothelial cells and its signaling. Am J Physiol Lung Cell Mol Physiol. 2005;289(2):L252-L260.
100. Pieper GM, Olds CL, Bub JD, et al. Transfection of human endothelial cells with HIV-1 tat gene activates NF-kappa B and enhances monocyte adhesion. Am J Physiol Heart Circ Physiol.2002;283(6): H2315-H2321.
101. Cota-Gomez A, Flores NC, Cruz C, et al. The human immunodeficiency virus-1 Tat protein activates human umbilical vein endothelial cell E-selectin expression via an NF-kappa B-dependent mechanism. J Biol Chem. 2002;277(17):14390-14399.
102. Chirivi RG, Taraboletti G, Bani MR, et al. Human immunodeficiency virus-1 (HIV-1)-Tat protein promotes migration of acquired immunodeficiency syndrome-related lymphoma cells and enhances their adhesion to endothelial cells. Blood. 1999;94(5):1747-1754.
103. Matzen KDA, oude Egbrink MG, Speth C, et al. HIV-1 Tat increases the adhesion of monocytes and T-cells to the endothelium in vitro and in vivo: implications for AIDS-associated vasculopathy. Virus Res. 2004;104(2):145-155.
104. Barillari G, Sgadari C, Fiorelli V, et al. The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the alpha5beta1 and alphavbeta3 integrins and by mobilizing sequestered basic fibroblast growth factor. Blood. 1999;94(2): 663-672.
105. Mitola S, Soldi R, Zanon I, et al. Identification of specific molecular structures of human immunodeficiency virus type 1 Tat relevant for its biological effects on vascular endothelial cells. J Virol. 2000;74(1):344-353.
106. Albini A, Soldi R, Giunciuglio D, et al. The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/ KDR receptor on vascular endothelial cells. Nat Med. 1996;2(12):1371-1375.
107. Wu RF, Gu Y, Xu YC, et al. Human immunodeficiency virus type 1 Tat regulates endothelial cell actin cytoske-letal dynamics through PAK1 activation and oxidant production. J Virol. 2004;78(2):779-789.
108. Avraham HK, Jiang S, Lee TH, et al. HIV-1 Tat-mediated effects on focal adhesion assembly and permeability in brain microvascular endothelial cells. J Immunol. 2004; 173(10):6228-6233.
109. Andras IE, Pu H, Deli MA, et al. HIV-1 Tat protein alters tight junction protein expression and distribution in cultured brain endothelial cells. J Neurosci Res. 2003; 74(2):255-265.
110. Toschi E, Barillari G, Sgadari C, et al. Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor. Mol Biol Cell. 2001;12(10):2934-2946.
111. Arese M, Ferrandi C, Primo L, et al. HIV-1 Tat protein stimulates in vivo vascular permeability and lymphomo-nonuclear cell recruitment. J Immunol. 2001;166(2): 1380-1388.
112. Margheri F, D'Alessio S, Serrati S, et al. The urokinase-type plasminogen activator, its receptor and u-PA inhibitor type-1 affect in vitro growth and invasion of Kaposi's sarcoma and capillary endothelial cells: role of HIV-Tat protein. Int J Oncol. 2005;27(1):223-235.
113. Fiorelli V, Barillari G, Toschi E, et al. IFN-gamma induces endothelial cells to proliferate and to invade the extracellular matrix in response to the HIV-1 Tat protein: implications for AIDS-Kaposi's sarcoma pathogenesis. J Immunol. 1999;162(2):1165-1170.
114. Barillari G, Sgadari C, Palladino C, et al. Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin. J Immunol. 1999;163(4):1929-1935.
115. Urbinati C, Mitola S, Tanghetti E, et al. Integrin alphavbeta3 as a target for blocking HIV-1 Tat-induced endothelial cell activation in vitro and angiogenesis in vivo. Arterioscler Thromb Vasc Biol. 2005;25(11):2315- 2320.
116. Park IW, Ullrich CK, Schoenberger E, et al. HIV-1 Tat induces microvascular endothelial apoptosis through caspase activation. J Immunol. 2001;167(5):2766-2771.
117. Zidovetzki R, Wang JL, Chen P, et al. Human immunodeficiency virus Tat protein induces interleukin 6 mRNA expression in human brain endothelial cells via protein kinase C- and cAMP-dependent protein kinase pathways. AIDS Res Hum Retroviruses. 1998;14(10): 825-833.
118. Wu RF, Ma Z, Myers DP, et al. HIV1 Tat activates dual Nox pathways leading to independent activation of ERK and JNK MAP kinases. J Biol Chem. Oct 16 2007.
119. Toborek M, Lee YW, Pu H, et al. HIV-Tat protein induces oxidative and inflammatory pathways in brain endothelium. J Neurochem. 2003;84(1):169-179.
120. Flores SC, Marecki JC, Harper KP, et al. Tat protein of human immunodeficiency virus type 1 represses expression of manganese superoxide dismutase in HeLa cells. Proc Natl Acad Sci U S A. 1993;90(16):7632-7636.
121. Westendorp MO, Shatrov VA, Schulze-Osthoff K, et al. HIV-1 Tat potentiates TNF-induced NF-kappa B activation and cytotoxicity by altering the cellular redox state. Embo J. 1995;14(3):546-554.
122. Gilbert M, Kirihara J, Mills J. Enzyme-linked immunoas-say for human immunodeficiency virus type 1 envelope glycoprotein 120. J Clin Microbiol. 1991;29(1):142-147.
123. Oh SK, Cruikshank WW, Raina J, et al. Identification of HIV-1 envelope glycoprotein in the serum of AIDS and ARC patients. J Acquir Immune Defic Syndr. 1992;5(3): 251-256.
124. Ren Z, Yao Q, Chen C. HIV-1 envelope glycoprotein 120 increases intercellular adhesion molecule-1 expression by human endothelial cells. Lab Invest. 2002;82(3):245-255.
125. Kanmogne GD, Schall K, Leibhart J, et al. HIV-1 gp120 compromises blood-brain barrier integrity and enhances monocyte migration across blood-brain barrier: implication for viral neuropathogenesis. J Cereb Blood Flow Metab. 2007;27(1):123-134.
126. Takano Y, Shimokado K, Hata Y, et al. HIV envelope protein gp120-triggered CD4+ T-cell adhesion to vascular endothelium is regulated via CD4 and CXCR4 receptors. Biochim Biophys Acta. 2007;1772(5):549-555.
127. Bragardo M, Buonfiglio D, Feito MJ, et al. Modulation of lymphocyte interaction with endothelium and homing by HIV-1 gp120. J Immunol. 1997;159(4):1619-1627.
128. Kanmogne GD, Primeaux C, Grammas P. HIV-1 gp120 proteins alter tight junction protein expression and brain endothelial cell permeability: implications for the pathogenesis of HIV-associated dementia. J Neuropathol Exp Neurol. 2005;64(6):498-505.
129. Cioni C, Annunziata P. Circulating gp120 alters the blood-brain barrier permeability in HIV-1 gp120 trans-genic mice. Neurosci Lett. 2002;330(3):299-301.
130. Didier N, Banks WA, Creminon C, et al. HIV-1-induced production of endothelin-1 in an in vitro model of the human blood-brain barrier. Neuroreport. 2002;13(9): 1179-1183.
131. Fiala M, Murphy T, MacDougall J, et al. HAART drugs induce mitochondrial damage and intercellular gaps and gp120 causes apoptosis. Cardiovasc Toxicol. 2004;4(4): 327-337.
132. Ullrich CK, Groopman JE, Ganju RK. HIV-1 gp120- and gp160-induced apoptosis in cultured endothelial cells is mediated by caspases. Blood. 2000;96(4):1438-1442.
133. Huang MB, Khan M, Garcia-Barrio M, et al. Apoptotic effects in primary human umbilical vein endothelial cell cultures caused by exposure to virion-associated and cell membrane-associated HIV-1 gp120. J Acquir Immune Defic Syndr. 2001;27(3):213-221.
134. Kanmogne GD, Kennedy RC, Grammas P. Analysis of human lung endothelial cells for susceptibility to HIV type 1 infection, coreceptor expression, and cytotoxicity of gp120 protein. AIDS Res Hum Retroviruses. 2001; 17(1):45-53.
135. Khan NA, Di Cello F, Stins M, et al. Gp120-mediated cytotoxicity of human brain microvascular endothelial cells is dependent on p38 mitogen-activated protein kinase activation. J Neurovirol. 2007;13(3):242-251.
136. Kanmogne GD, Kennedy RC, Grammas P. HIV-1 gp120 proteins and gp160 peptides are toxic to brain endothelial cells and neurons: possible pathway for HIV entry into the brain and HIV-associated dementia. J Neuropathol Exp Neurol. 2002;61(11):992-1000.
137. Huang MB, Bond VC. Involvement of protein kinase C in HIV-1 gp120-induced apoptosis in primary endothelium. J Acquir Immune Defic Syndr. 2000;25(5):375-389.
138. Price TO, Uras F, Banks WA, et al. A novel antioxidant N-acetylcysteine amide prevents gp120- and Tat-induced oxidative stress in brain endothelial cells. Exp Neurol. 2006;201(1):193-202.
139. Schecter AD, Berman AB, Yi L, et al. HIV envelope gp120 activates human arterial smooth muscle cells. Proc Natl Acad Sci U S A. 2001;98(18):10142-10147.
140. Jana A, Pahan K. Human immunodeficiency virus type 1 gp120 induces apoptosis in human primary neurons through redox-regulated activation of neutral sphingo-myelinase. J Neurosci. 2004;24(43):9531-9540.
141. Henderson WW, Ruhl R, Lewis P, et al. Human immunodeficiency virus (HIV) type 1 Vpu induces the expression of CD40 in endothelial cells and regulates HIV-induced adhesion of B-lymphoma cells. J Virol. 2004;78(9):4408-4420.
142. Acheampong E, Mukhtar M, Parveen Z, et al. Ethanol strongly potentiates apoptosis induced by HIV-1 proteins in primary human brain microvascular endothelial cells. Virology. 2002;304(2):222-234.
143. Choi J, Walker J, Boichuk S, et al. Human endothelial cells enhance human immunodeficiency virus type 1 replication in CD4+ T cells in a Nef-dependent manner in vitro and in vivo. J Virol. 2005;79(1): 264-276.
144. Biggs TE, Cooke SJ, Barton CH, et al. Induction of activator protein 1 (AP-1) in macrophages by human immunodeficiency virus type-1 NEF is a cell-type-specific response that requires both hck and MAPK signaling events. J Mol Biol. 1999;290(1):21-35.
145. Varin A, Manna SK, Quivy V, et al. Exogenous Nef protein activates NF-kappa B, AP-1, and c-Jun N-terminal kinase and stimulates HIV transcription in promonocytic cells. Role in AIDS pathogenesis. J Biol Chem. 2003;278(4):2219-2227.
146. Olivetta E, Pietraforte D, Schiavoni I, et al. HIV-1 Nef regulates the release of superoxide anions from human macrophages. Biochem J. 2005;390(Pt 2):591-602.
147. Zheng YH, Plemenitas A, Fielding CJ, et al. Nef increases the synthesis of and transports cholesterol to lipid rafts and HIV-1 progeny virions. Proc Natl Acad Sci U S A. 2003;100(14):8460-8465.
148. Mujawar Z, Rose H, Morrow MP, et al. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol. 2006;4(11):e365.
149. Bukrinsky M, Sviridov D. Human immunodeficiency virus infection and macrophage cholesterol metabolism. J Leukoc Biol. 2006;80(5):1044-1051.
150. OARAC. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. December 1, 2007. available at: http://aidsinfo. nih.gov.
151. Lewis W, Day BJ, Copeland WC. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov. 2003;2(10):812-822.
152. Dagan T, Sable C, Bray J, et al. Mitochondrial dysfunction and antiretroviral nucleoside analog toxici-ties: what is the evidence? Mitochondrion. 2002;1(5): 397-412.
153. Pinti M, Salomoni P, Cossarizza A. Anti-HIV drugs and the mitochondria. Biochim Biophys Acta. 2006; 1757(5-6):700-707.
154. Sutliff RL, Dikalov S, Weiss D, et al. Nucleoside reverse transcriptase inhibitors impair endothelium-dependent relaxation by increasing superoxide. Am J Physiol Heart Circ Physiol. 2002;283(6):H2363-H2370.
155. Jiang B, Hebert VY, Zavecz JH, et al. Antiretrovirals induce direct endothelial dysfunction in vivo. J Acquir Immune Defic Syndr. 2006;42(4):391-395.
156. Hebert VY, Crenshaw BL, Romanoff RL, et al. Effects of HIV drug combinations on endothelin-1 and vascular cell proliferation. Cardiovasc Toxicol. 2004;4(2):117-131.
157. Jiang B, Hebert VY, Li Y, et al. HIV antiretroviral drug combination induces endothelial mitochondrial dysfunction and reactive oxygen species production, but not apoptosis. Toxicol Appl Pharmacol. 2007;224(1): 60-71.
158. Gross NJ, Getz GS, Rabinowitz M. Apparent turnover of mitochondrial deoxyribonucleic acid and mitochondrial phospholipids in the tissues of the rat. J Biol Chem. 1969;244(6):1552-1562.
159. de la Asuncion JG, Del Olmo ML, Gomez-Cambronero LG, et al. AZT induces oxidative damage to cardiac mitochondria: protective effect of vitamins C and E. Life Sci. 2004;76(1):47-56.
160. Yamaguchi T, Katoh I, Kurata S. Azidothymidine causes functional and structural destruction of mitochondria, glutathione deficiency and HIV-1 promoter sensitization. Eur J Biochem. 2002;269(11):2782-2788.
161. Papparella I, Ceolotto G, Berto L, et al. Vitamin C prevents zidovudine-induced NAD(P)H oxidase activation and hypertension in the rat. Cardiovasc Res. 2007; 73(2):432-438.
162. Cazzalini O, Lazze MC, Iamele L, et al. Early effects of AZT on mitochondrial functions in the absence of mitochondrial DNA depletion in rat myotubes. Biochem Pharmacol. 2001;62(7):893-902.
163. McKee EE, Bentley AT, Hatch M, et al. Phosphorylation of thymidine and AZT in heart mitochondria: elucidation of a novel mechanism of AZT cardiotoxicity. Cardiovasc Toxicol. 2004;4(2):155-167.
164. Song S, Wheeler LJ, Mathews CK. Deoxyribonucleotide pool imbalance stimulates deletions in HeLa cell mito-chondrial DNA. J Biol Chem. 2003;278(45):43893-43896.
165. Pan-Zhou XR, Cui L, Zhou XJ, et al. Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells. Antimicrob Agents Chemother. 2000;44(3):496-503.
166. Szabados E, Fischer GM, Toth K, et al. Role of reactive oxygen species and poly-ADP-ribose polymerase in the development of AZT-induced cardiomyopathy in rat. Free Radic Biol Med. 1999;26(3-4):309-317.
167. Yan JP, Ilsley DD, Frohlick C, et al. 3′-Azidothymidine (zidovudine) inhibits glycosylation and dramatically alters glycosphingolipid synthesis in whole cells at clinically relevant concentrations. J Biol Chem. 1995; 270(39):22836-22841.
168. Valenti D, Barile M, Passarella S. AZT inhibition of the ADP/ATP antiport in isolated rat heart mitochondria. Int J Mol Med. 2000;6(1):93-96.
169. Lund KC, Wallace KB. Adenosine 3′,5′-cyclic monopho-sphate (cAMP)-dependent phosphoregulation of mito-chondrial complex I is inhibited by nucleoside reverse transcriptase inhibitors. Toxicol Appl Pharmacol. 2008; 226(1):94-106.
170. Cote HC. Possible ways nucleoside analogues can affect mitochondrial DNA content and gene expression during HIV therapy. Antivir Ther. 2005;10(Suppl 2):M3-M11.
171. Kontorinis N, Dieterich DT. Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin Liver Dis. 2003;23(2):173-182.
172. de Saint Martin L, Vandhuick O, Guillo P, et al. Premature atherosclerosis in HIV positive patients and cumulated time of exposure to antiretroviral therapy (SHIVA study). Atherosclerosis. 2006;185(2):361-367.
173. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356(17):1723- 1735.
174. Thiebaut R, El-Sadr WM, Friis-Moller N, et al. Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antivir Ther. 2005;10(7):811-823.
175. Tashima KT, Bausserman L, Alt EN, et al. Lipid changes in patients initiating efavirenz- and indinavir-based antiretroviral regimens. HIV Clin Trials. 2003;4(1):29-36.
176. van der Valk M, Kastelein JJ, Murphy RL, et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. Aids. 2001;15(18):2407-2414.
177. Murphy RL, Smith WJ. Switch studies: a review. HIV Med. 2002;3(2):146-155.
178. Young J, Weber R, Rickenbach M, et al. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antivir Ther. 2005;10(5):585-591.
179. van Wijk JP, de Koning EJ, Cabezas MC, et al. Functional and structural markers of atherosclerosis in human immunodeficiency virus-infected patients. J Am Coll Cardiol. 2006;47(6):1117-1123.
180. Johnsen S, Dolan SE, Fitch KV, et al. Carotid intimal medial thickness in human immunodeficiency virus-infected women: effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome. J Clin Endocrinol Metab. 2006;91(12):4916-4924.
181. Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation. 2001;104(3): 257-262.
182. Shankar SS, Dube MP, Gorski JC, et al. Indinavir impairs endothelial function in healthy HIV-negative men. Am Heart J. 2005;150(5):933.
183. Blanco JJ, Garcia IS, Cerezo JG, et al. Endothelial function in HIV-infected patients with low or mild cardiovascular risk. J Antimicrob Chemother. 2006;58(1):133-139.
184. Currier JS, Kendall MA, Henry WK, et al. Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults. Aids. 2007;21(9):1137-1145.
185. Currier JS, Kendall MA, Zackin R, et al. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. Aids. 2005;19(9):927-933.
186. Grubb JR, Dejam A, Voell J, et al. Lopinavir-ritonavir: effects on endothelial cell function in healthy subjects. J Infect Dis. 2006;193(11):1516-1519.
187. Nolan D, Watts GF, Herrmann SE, et al. Endothelial function in HIV-infected patients receiving protease inhibitor therapy: does immune competence affect cardiovascular risk? Qjm. 2003;96(11):825-832.
188. Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005;165(10):1179-1184.
189. Riddler SA, Li X, Chu H, et al. Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy. HIV Med. 2007;8(5):280-287.
190. Fisher SD, Miller TL, Lipshultz SE. Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis. Atherosclerosis. 2006;185(1):1-11.
191. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. Aids. 2003;17(8):1179-1193.
192. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349(21):1993-2003.
193. Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet. 2002;360(9347):1747-1748.
194. Mary-Krause M, Cotte L, Simon A, et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. Aids. 2003;17(17):2479-2486.
195. Wang X, Chai H, Yao Q, et al. Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction. J Acquir Immune Defic Syndr. 2007;44(5):493-499.
196. Zhong DS, Lu XH, Conklin BS, et al. HIV protease inhibitor ritonavir induces cytotoxicity of human en-dothelial cells. Arterioscler Thromb Vasc Biol. 2002; 22(10):1560-1566.
197. Chen C, Lu XH, Yan S, et al. HIV protease inhibitor ritonavir increases endothelial monolayer permeability. Biochem Biophys Res Commun. 2005;335(3):874-882.
198. Mondal D, Pradhan L, Ali M, et al. HAART drugs induce oxidative stress in human endothelial cells and increase endothelial recruitment of mononuclear cells: exacerbation by inflammatory cytokines and amelioration by antioxidants. Cardiovasc Toxicol. 2004;4(3): 287-302.
199. Baliga RS, Liu C, Hoyt DG, et al. Vascular endothelial toxicity induced by HIV protease inhibitor: evidence of oxidant-related dysfunction and apoptosis. Cardiovasc Toxicol. 2004;4(2):199-206.
200. Conklin BS, Fu W, Lin PH, et al. HIV protease inhibitor ritonavir decreases endothelium-dependent vasorelaxation and increases superoxide in porcine arteries. Cardiovasc Res. 2004;63(1):168-175.
201. Chai H, Yang H, Yan S, et al. Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries. J Acquir Immune Defic Syndr. 2005;40(1):12-19.
202. Chai H, Yan S, Lin P, et al. Curcumin blocks HIV protease inhibitor ritonavir-induced vascular dysfunction in porcine coronary arteries. J Am Coll Surg. 2005;200(6):820-830.
203. Chai H, Zhou W, Lin P, et al. Ginsenosides block HIV protease inhibitor ritonavir-induced vascular dysfunction of porcine coronary arteries. Am J Physiol Heart Circ Physiol. 2005;288(6):H2965-H2971.
204. Fu W, Chai H, Yao Q, et al. Effects of HIV protease inhibitor ritonavir on vasomotor function and endothelial nitric oxide synthase expression. J Acquir Immune Defic Syndr. 2005;39(2):152-158.
205. Bourlier V, Zakaroff-Girard A, De Barros S, et al. Protease inhibitor treatments reveal specific involvement of matrix metalloproteinase-9 in human adipocyte differentiation. J Pharmacol Exp Ther. 2005;312(3):1272-1279.
206. Xu A, Yin S, Wong L, et al. Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice. Endocrinology. 2004;145(2):487-494.
207. Shahmanesh M, Das S, Stolinski M, et al. Antiretroviral treatment reduces very-low-density lipoprotein and inter- mediate-density lipoprotein apolipoprotein B fractional catabolic rate in human immunodeficiency virus-infected patients with mild dyslipidemia. J Clin Endocrinol Metab. 2005;90(2):755-760.
208. Lee GA, Seneviratne T, Noor MA, et al. The metabolic effects of lopinavir/ritonavir in HIV-negative men. Aids. 2004;18(4):641-649.
209. Zhou H, Pandak WM Jr, Lyall V, et al. HIV protease inhibitors activate the unfolded protein response in macrophages: implication for atherosclerosis and cardiovascular disease. Mol Pharmacol. 2005;68(3):690-700.
210. Dressman J, Kincer J, Matveev SV, et al. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J Clin Invest. 2003;111(3):389-397.
211. Bradshaw EL, Li XA, Guerin T, et al. Nucleoside reverse transcriptase inhibitors prevent HIV protease inhibitor-induced atherosclerosis by ubiquitination and degradation of protein kinase C. Am J Physiol Cell Physiol. 2006; 291(6):C1271-C1278.
212. Wang X, Mu H, Chai H, et al. Human immunodeficiency virus protease inhibitor ritonavir inhibits cholesterol efflux from human macrophage-derived foam cells. Am J Pathol. 2007;171(1):304-314.
213. Zhou H, Jarujaron S, Gurley EC, et al. HIV protease inhibitors increase TNF-alpha and IL-6 expression in macrophages: involvement of the RNA-binding protein HuR. Atherosclerosis. 2007;195(1):e134-e143.
214. Stein JH, Merwood MA, Bellehumeur JL, et al. Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. Am Heart J. 2004;147(4):E18.